A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug

The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.

Takeda announced the approval of Fruzaqla in previously treated metastatic colorectal cancer • Source: Shutterstock

Roughly a month after suffering a setback in its oncology franchise with the market withdrawal of a drug for lung cancer, Takeda Pharmaceutical Co. Ltd. got some welcome news with the approval of a colorectal cancer medication that it licensed for more than $1bn from its China-based developer earlier this year.

The US Food and Drug Administration approved Fruzaqla (fruquintinib) on 8 November, ahead of its 30 November action date, for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip